To summarize the clinical therapeutic experience in managing Acinetobacter baumannii infection originating from a kidney donor.

A single-case analysis was conducted on the treatment of Acinetobacter baumannii infection derived from a kidney donor. During the ex vivo kidney preservation phase，the organ was continuously perfused with a tigecycline-containing solution at low temperature for approximately 10 hours，followed by transplantation. Postoperatively，systemic therapy with tigecycline combined with other antibiotics was continued for 6 days. During treatment，hepatic and renal function，serum amylase，lipase，and complete blood count (CBC) were monitored dynamically. Microbiological cultures of urine and drainage fluid were regularly repeated.

From postoperative day (POD) 3 onward，urine and drainage fluid cultures were repeatedly negative. Throughout the treatment period，the patient′s liver function tests，serum amylase，and lipase levels remained within normal limits. Blood urea nitrogen (BUN) and creatinine levels gradually returned to near-normal ranges. No significant drug-related adverse reactions were observed. The patient was successfully discharged on postoperative day 22.

The use of a tigecycline-containing perfusion solution during ex vivo kidney cold preservation，combined with a short-course of postoperative systemic anti-infective therapy，can safely and effectively eradicate donor-derived Acinetobacter baumannii.